X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (78) 78
index medicus (66) 66
female (62) 62
male (62) 62
middle aged (50) 50
hematology (46) 46
aged (41) 41
adult (40) 40
oncology (29) 29
prognosis (23) 23
treatment outcome (22) 22
aged, 80 and over (19) 19
transplantation (19) 19
risk factors (17) 17
survival (17) 17
analysis (15) 15
clinical trials (14) 14
adolescent (13) 13
antineoplastic combined chemotherapy protocols - therapeutic use (12) 12
children (12) 12
medical research (12) 12
multiple myeloma (12) 12
patients (12) 12
prospective studies (12) 12
child (11) 11
immunology (11) 11
stem cells (11) 11
cancer (10) 10
follow-up studies (10) 10
medicine & public health (10) 10
survival analysis (10) 10
therapy (10) 10
combined modality therapy (9) 9
comorbidity (9) 9
hematology, oncology and palliative medicine (9) 9
kaplan-meier estimate (9) 9
medicine, experimental (9) 9
pediatrics (9) 9
young adult (9) 9
age (8) 8
chemotherapy (8) 8
child, preschool (8) 8
germany (8) 8
incidence (8) 8
leukemia (8) 8
multiple myeloma - pathology (8) 8
multiple myeloma - therapy (8) 8
abridged index medicus (7) 7
cancer-patients (7) 7
care and treatment (7) 7
efficacy (7) 7
further section · weitere sektionen (7) 7
health aspects (7) 7
hematopoietic stem cell transplantation (7) 7
infant (7) 7
multiple myeloma - drug therapy (7) 7
myelodysplastic syndrome (7) 7
quality of life (7) 7
risk (7) 7
survival rate (7) 7
transplantation, homologous (7) 7
adults (6) 6
antineoplastic agents - therapeutic use (6) 6
antineoplastic combined chemotherapy protocols - adverse effects (6) 6
elderly-patients (6) 6
epidemiology (6) 6
germany - epidemiology (6) 6
hematopoietic stem cells (6) 6
infant, newborn (6) 6
medicine (6) 6
multiple myeloma - diagnosis (6) 6
multiple myeloma - epidemiology (6) 6
neoplasm staging (6) 6
time factors (6) 6
transplantation, autologous (6) 6
usage (6) 6
acute myeloid-leukemia (5) 5
bone marrow (5) 5
cohort studies (5) 5
disease (5) 5
disease-free survival (5) 5
double-blind method (5) 5
drug administration schedule (5) 5
follow-up (5) 5
geriatric assessment (5) 5
hematopoietic-cell transplantation (5) 5
leukemia, myeloid, acute - therapy (5) 5
methotrexate - administration & dosage (5) 5
multiple myeloma - metabolism (5) 5
outcome (5) 5
proportional hazards models (5) 5
quality-of-life (5) 5
recurrence (5) 5
respiratory tract infections - epidemiology (5) 5
risk assessment (5) 5
surveys and questionnaires (5) 5
versus-host-disease (5) 5
adhd (4) 4
age factors (4) 4
antineoplastic combined chemotherapy protocols - administration & dosage (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
BMC CANCER, ISSN 1471-2407, 03/2019, Volume 19, Issue 1, pp. 287 - 7
BackgroundPrimary central nervous system lymphoma (PCNSL) is a diffuse large B-cell lymphoma (DLBCL) confined to the central nervous system (CNS) with rising... 
1ST-LINE TREATMENT | CHEMOIMMUNOTHERAPY | PROGNOSIS | METHOTREXATE | High-dose chemotherapy (HDT) | Primary central nervous system lymphoma (PCNSL) | Elderly patients | INTERNATIONAL EXTRANODAL LYMPHOMA | Autologous stem cell transplantation (ASCT) | RANDOMIZATION | ONCOLOGY | RECURRENT PRIMARY CNS | QUALITY-OF-LIFE | RADIOTHERAPY | NERVOUS-SYSTEM LYMPHOMA | Thiotepa - therapeutic use | Lymphoma, Large B-Cell, Diffuse - drug therapy | Cytarabine - therapeutic use | Humans | Antineoplastic Protocols | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Central Nervous System Neoplasms - therapy | Cytarabine - adverse effects | Methotrexate - therapeutic use | Combined Modality Therapy - adverse effects | Induction Chemotherapy - adverse effects | Methotrexate - adverse effects | Rituximab - therapeutic use | Lymphoma, Large B-Cell, Diffuse - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Progression-Free Survival | Hematopoietic Stem Cell Transplantation - adverse effects | Transplantation, Autologous - adverse effects | Aged | Central Nervous System Neoplasms - drug therapy | Rituximab - adverse effects | Thiotepa - adverse effects | Chemotherapy | Usage | Care and treatment | Nervous system cancer | Stem cells | Aged patients | Transplantation | Diagnosis | Health aspects | Cancer
Journal Article
LEUKEMIA, ISSN 0887-6924, 12/2019, Volume 33, Issue 12, pp. 2956 - 2962
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2011, Volume 29, Issue 25, pp. 3402 - 3407
Journal Article
British Journal of Haematology, ISSN 0007-1048, 10/2017, Volume 179, Issue 1, pp. 36 - 49
Summary Cell adhesion‐mediated drug resistance (CAM‐DR) by the bone marrow (BM) is fundamental to multiple myeloma (MM) propagation and survival. Targeting BM... 
multiple myeloma | stroma cells | drug resistance | adhesion molecules | stem cell mobilizing/homing | VIVO | AMD3100 | BONE-MARROW NICHE | TUMOR | BORTEZOMIB | IN-VITRO | INHIBITION | MICROENVIRONMENT | CHEMOKINE RECEPTOR | HEMATOLOGY | EXPRESSION | Phosphorylation | Coculture Techniques | Humans | Middle Aged | Protein Multimerization | Heterocyclic Compounds - pharmacology | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | Multiple Myeloma - drug therapy | Chemokine CXCL12 - genetics | Receptors, CXCR - metabolism | Stromal Cells - drug effects | Aged, 80 and over | Adult | Bone Marrow Cells - drug effects | Female | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Aptamers, Nucleotide - pharmacology | Multiple Myeloma - diagnosis | Receptors, CXCR - genetics | Stromal Cells - metabolism | Immunophenotyping | Cell Adhesion - drug effects | Multiple Myeloma - metabolism | Protein Transport | Chemokine CXCL12 - metabolism | Chromosome Aberrations | Biomarkers | Cell Line, Tumor | Aged | Heterocyclic Compounds - therapeutic use | Neoplasm Staging | Oligopeptides - pharmacology | Bone Marrow Cells - metabolism | Multiple Myeloma - genetics | Mitogen-Activated Protein Kinase 1 - metabolism | Corticosteroids | Drug therapy | Drug resistance | Analysis | Multiple myeloma | Stem cells | Cell culture | CXCL12 protein | Bortezomib | Dexamethasone | CD49d antigen | Propagation | Feasibility studies | Stroma | Cytotoxicity | Chemotaxis | CXCR4 protein | Proteasome inhibitors | Cell adhesion & migration | CD44 antigen | Cell adhesion | Bone marrow
Journal Article
Journal Article
by Mathew, N.R and Baumgartner, F and Braun, L and O'Sullivan, D and Thomas, S and Waterhouse, M and Muller, T.A and Hanke, K and Taromi, S and Apostolova, P and Illert, A.L and Melchinger, W and Duquesne, S and Schmitt-Graeff, A and Osswald, L and Yan, K.L and Weber, A and Tugues, S and Spath, S and Pfeifer, D and Follo, M and Claus, R and Lubbert, M and Rummelt, C and Bertz, H and Wasch, R and Haag, J and Schmidts, A and Schultheiss, M and Bettinger, D and Thimme, R and Ullrich, E and Tanriver, Y and Vuong, G.L and Arnold, R and Hemmati, P and Wolf, D and Ditschkowski, M and Jilg, C and Wilhelm, K and Leiber, C and Gerull, S and Halter, J and Lengerke, C and Pabst, T and Schroeder, T and Kobbe, G and Rosler, W and Doostkam, S and Meckel, S and Stabla, K and Metzelder, S.K and Halbach, S and Brummer, T and Hu, Z and Dengjel, J and Hackanson, B and Schmid, C and Holtick, U and Scheid, C and Spyridonidis, A and Stolzel, F and Ordemann, R and Muller, L.P and Sicre-de-Fontbrune, F and Ihorst, G and Kuball, J and Ehlert, J.E and Feger, D and Wagner, E.M and Cahn, J.Y and Schnell, J and Kuchenbauer, F and Bunjes, D and Chakraverty, R and Richardson, S and Gill, S and Kroger, N and Ayuk, F and Vago, L and Ciceri, F and Muller, A.M and Kondo, T and Teshima, T and Klaeger, S and Kuster, B and Kim, D.D.H and Weisdorf, D and Velden, W.J. van der and Dorfel, D and Bethge, W and Hilgendorf, I and Hochhaus, A and Anieux, G and Borries, M and Busch, H and Magenau, J and Reddy, P and Labopin, M and Antin, J.H., et al
Nature Medicine, ISSN 1078-8956, 2018, Volume 24, Issue 3, pp. 282 - 291
Journal Article